Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy

被引：1
|
作者：
Mueschen, Lars H. [1 ]
Koerner, Gudrun [1 ]
Gingele, Stefan [1 ]
Haenselmann, Anja [2 ]
Bavendiek, Udo [2 ]
Skripuletz, Thomas [1 ]
机构：
[1] Hannover Med Sch, Dept Neurol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[2] Hannover Med Sch, Dept Cardiol & Angiol, Hannover, Germany
来源：
MUSCLE & NERVE | 2021年 / 64卷 / 03期
关键词：
DISABILITY SCALE;
D O I：
10.1002/mus.27338
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E11 / E13
页数：3
相关论文
共 50 条
  • [1] Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis
    Yang, Junyi
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (02) : 95 - 99
  • [2] Patisiran in hereditary transthyretin-mediated amyloidosis
    Luigetti, Marco
    Servidei, Serenella
    LANCET NEUROLOGY, 2021, 20 (01): : 21 - 23
  • [3] Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Gorevic, Peter
    Franklin, Jaclyn
    Chen, Jihong
    Sajeev, Gautam
    Wang, Jessie C. H.
    Lin, Hollis
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (01) : 121 - 129
  • [4] Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation
    Schmidt, Hartmut H.
    Wixner, Jonas
    Plante-Bordeneuve, Violaine
    Munoz-Beamud, Francisco
    Llado, Laura
    Gillmore, Julian D.
    Mazzeo, Anna
    Li, Xingyu
    Arum, Seth
    Jay, Patrick Y.
    Adams, David
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (06) : 1646 - 1657
  • [5] An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Plante-Bordeneuve, Violaine
    Lin, Hollis
    Gollob, Jared
    Agarwal, Sonalee
    Betts, Marissa
    Fahrbach, Kyle
    Chitnis, Madhura
    Polydefkis, Michael
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (04) : 473 - 481
  • [6] Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
    Dixon, Stacy
    Kang, Xuan
    Quan, Dianna
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 973 - 981
  • [7] Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Labeyrie, Celine
    Merkel, Madeline
    Sethi, Sakshi
    Popadic, Lyuba
    Yang, Hongbo
    Sweetser, Marianne T.
    Lin, Hollis
    Adams, David
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (09)
  • [8] Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis
    Kristen, Arnt, V
    Ajroud-Driss, Senda
    Conceicao, Isabel
    Gorevic, Peter
    Kyriakides, Theodoros
    Obici, Laura
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2019, 9 (01) : 5 - 24
  • [9] COST OF INOTERSEN AND PATISIRAN FOR THE TREATMENT OF ADULTS WITH POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN CANADA, GERMANY, AND ITALY
    Brown, D.
    Vera-Llonch, M.
    Shaff, M.
    Rolli, A.
    Vega, M.
    Blum, M.
    Nestler-Parr, S.
    Jiresch, M.
    Weycker, D.
    VALUE IN HEALTH, 2020, 23 : S606 - S607
  • [10] Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy
    Ioannou, Adam
    Fontana, Marianna
    Gillmore, Julian D.
    HEART INTERNATIONAL, 2023, 17 (01): : 27 - 35
12345